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Abstract
Rationale: Sutezolid (PNU-100480) is a linezolid analog with superior bactericidal activity against Mycobacterium tuberculosis
in the hollow fiber, whole blood and mouse models. Like linezolid, it is unaffected by mutations conferring resistance to
standard TB drugs. This study of sutezolid is its first in tuberculosis patients.
Methods: Sputum smear positive tuberculosis patients were randomly assigned to sutezolid 600 mg BID (N = 25) or
1200 mg QD (N= 25), or standard 4-drug therapy (N = 9) for the first 14 days of treatment. Effects on mycobacterial burden
in sputum (early bactericidal activity or EBA) were monitored as colony counts on agar and time to positivity in automated
liquid culture. Bactericidal activity was also measured in ex vivo whole blood cultures (whole blood bactericidal activity or
WBA) inoculated with M. tuberculosis H37Rv.
Results: All patients completed assigned treatments and began subsequent standard TB treatment according to protocol.
The 90% confidence intervals (CI) for bactericidal activity in sputum over the 14 day interval excluded zero for all treatments
and both monitoring methods, as did those for cumulative WBA. There were no treatment-related serious adverse events,
premature discontinuations, or dose reductions due to laboratory abnormalities. There was no effect on the QT interval.
Seven sutezolid-treated patients (14%) had transient, asymptomatic ALT elevations to 173634 U/L on day 14 that
subsequently normalized promptly; none met Hy’s criteria for serious liver injury.
Conclusions: The mycobactericidal activity of sutezolid 600 mg BID or 1200 mg QD was readily detected in sputum and
blood. Both schedules were generally safe and well tolerated. Further studies of sutezolid in tuberculosis treatment are
warranted.
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Introduction
Mycobacterium tuberculosis resistant to current first-line anti-
tuberculosis agents is a serious and growing global health threat,
causing at least 444,000 new tuberculosis (TB) cases and 150,000
deaths annually [1]. Treatments for drug-resistant (DR) TB are
inferior to those for drug-sensitive disease, with lower cure rates,
reduced safety and tolerability, and prolonged treatment require-
ments. Oxazolidinone antimicrobials are increasingly viewed as
candidates for inclusion in new regimens for DR-TB, as they have a
distinct mechanism of action (binding to the 23S ribosome, thereby
blocking microbial protein synthesis) without cross-resistance to
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existing TB drugs. However, in the case of linezolid, the only
currently licensed oxazolidinone, serious hematologic and neuro-
logic toxicities arise during long term use due to inhibition of
mitochondrial protein synthesis that often require dose reduction or
discontinuation [2,3]. Thus, for the promise of oxazolidinones for
TB to be realized, new drugs in this class with superior efficacy and
reduced toxicity must be developed.
Sutezolid (PNU-100480) is a thiomorpholinyl analog of linezolid
with preliminary evidence for superior efficacy against M.
tuberculosis. In the mouse model, sutezolid shortens standard
treatment by 1 month, whereas linezolid does not [4]; in the
whole blood culture model, the maximal bactericidal activity of
sutezolid (20.42 log/day) is more than twice that of linezolid (2
0.16 log/day, P,0.001) [5]. Time-dependent killing has been
reported in whole blood and hollow fibers [5,6]. Bactericidal
activity against intracellular mycobacteria is mainly due to the
parent (PNU-100480), whereas a sulfoxide metabolite (PNU-
101603) contributes significantly to activity against extracellular
mycobacteria [6]. Phase 1 studies revealed no abnormal hema-
tologic or biochemical findings, nor instances of peripheral or
ophthalmic neuropathy, in healthy volunteers administered
sutezolid 600 mg twice daily for 28 days [5], potentially indicating
a safety profile superior to similarly dosed linezolid.
In the present study, sutezolid was administered at doses of
600 mg twice daily or 1200 mg once daily for 14 days to patients
with newly diagnosed drug-sensitive pulmonary tuberculosis, to
assess its safety, tolerability, pharmacokinetics, and early bacteri-
cidal activity (EBA) in sputum. The main objective of the study
was to determine if sutezolid treatment resulted in significant
reduction in log sputum CFU counts with 5%–95% confidence
intervals that excluded zero. The study also examined bactericidal
activity in ex vivo whole blood cultures infected with M. tuberculosis
(whole blood bactericidal activity or WBA), as well as resistance
prevention in sputum (measured as changes in MICs during the
treatment period).
Methods
Protocol
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Subjects
All subjects provided written informed consent according to
ICH guidelines. Subjects consisted of men and women aged 18–65
years, with chest radiographs consistent with pulmonary tubercu-
losis, positive sputum acid-fast smears, culture or molecular
confirmation of drug-susceptible M. tuberculosis, random blood
glucose ,150 mg/dL, hemoglobin .8 g/dL, serum creatinine ,
2 mg/dL, AST ,3x ULN, total bilirubin ,1.3 mg/dL. Serologic
testing was not performed for hepatitis B or C, nor were these
exclusion criteria. Subjects were either HIV-1 uninfected, or HIV-
1 infected with CD4 T cell counts .350/mm3 and not currently
receiving anti-retroviral therapy. Patients receiving monoamine
oxidase (MAO) inhibitors, tricyclic antidepressants, or adrenergic
agonists such as pseudoephedrine or phenylpropanolamine within
the preceding 7 days were excluded (due to potential concerns
regarding MAO-A inhibition), as were patients who had received
drugs with anti-tuberculosis activity within the preceding 6
months, had a positive test for urinary isoniazid metabolite at
the time of screening, or who had significant hemoptysis.
Treatments
After providing written informed consent, subjects were
randomly assigned in blocks of 7–9 to sutezolid 600 mg BID
(N=25) or 1200 mg QD (N=25), or to a positive control of
weight adjusted fixed dose combination tablets (Rifafour e275;
Sanofi-Aventis, Midrand, South Africa) consisting of isoniazid,
rifampin, pyrazinamide, and ethambutol (HRZE, N=9). The
purpose of this group was to ascertain comparability of laboratory
methods to other EBA trials. Sutezolid was administered as
200 mg tablets. All treatments were administered on an inpatient
basis. Neither subjects nor investigators were blinded to assigned
treatment. Laboratory staff performing the sputum and whole
blood assays was unaware of treatment allocation. After discharge
all subjects were referred for a full course of standard antituber-
culosis treatment.
Evaluations
Symptoms and physical exam were monitored daily. Electro-
cardiograms were obtained at baseline, day 1, and day 14. Routine
blood and urine safety tests were monitored on days 1, 14, and 42.
Pooled sputum samples were collected for 16 hrs on days 21, 0, 1,
2, 3, 4, 6, 8, 10, 12, and 14, beginning in the afternoon of the
specified study day and continuing through the next morning.
Days 21 and 0 were considered baseline days for statistical
calculations. Treatment began in the morning of day 1, after
collection of the day 0 sputum sample was completed. Sputum
specimens were stored on ice at the bedside during collection and
transported to the central laboratory (Department of Biomedical
Sciences, Stellenbosch University, Tygerberg, South Africa) at 4uC
the next morning. Pooled specimens were homogenized by stirring
for 30 minutes, then digested with an equal volume of Sputasol
(Oxoid, Cambridge UK) at a final dithiothreitol concentration of
10%. An aliquot was removed and a series of 10-fold dilutions
prepared in saline with Tween 80 for log CFU determination on
7H11 agar with Selectatab (polymyxin B, ticarcillin, amphotericin
B, trimethoprim, MAST, Bootle, Merseyside, UK) added. Log
CFU determinations were performed on specimens collected on
days 21, 0, 1, 2, 4, 6, 10, and 14. A second aliquot was
decontaminated with 1% NaOH-N-acetyl-L-cysteine, diluted with
PBS and centrifuged at 4uC and 3000 g for 15 minutes. The
supernatant was discarded and the pellet resuspended in 1.5 ml
PBS. 500 ml of this was used to inoculate a Mycobacteria Growth
Indicator Tube (MGIT, Becton Dickinson, Sparks, USA) supple-
mented with OADC (oleic acid, albumin, dextrose, catalase) and
PANTA (polymyxin B, amphotericin B, nalidixic acid, trimetho-
prim, azlocillin). MGITs were incubated at 37uC in a BACTEC
MGIT 960 instrument until flagged positive or for a maximum of
42 days in case no growth was detected. Time to positivity (TTP)
in MGIT cultures was recorded for all specimens. Contamination
was excluded by placing one drop of positive liquid culture on a
blood agar plate (NHLS, Cape Town, South Africa) and by
incubating for 48 hours at 37uC without visible growth. Contam-
inated cultures were excluded from analysis.
Blood was collected for WBA on prior to treatment on day 1.
Blood was collected for PK and WBA 8 and 12 hrs post dose on
day 13, and at 0, 1, 2, 3, and 6 hrs post dose on day 14. Plasma
was separated immediately after collection and stored at 220uC
for PK determinations. Total plasma concentrations of PNU-
100480 and PNU-101603 were determined using a validated LC-
MS/MS method by Advion BioServices (Ithaca, NY, USA), as
previously described [7]. Blood for WBA was stored at room
temperature with slow constant rotation until a full set of samples
for a subject had been collected, at which time they were
transported to the laboratory. WBA against M. tuberculosis H37Rv
Sutezolid EBA and WBA
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was determined as previously described [7]. Briefly, M. tuberculosis
H37Rv was grown in MGIT and frozen in aliquots at 280C. A
titration experiment determined the relationship between inocu-
lum size and TTP, and identified the volume positive in 5.5 days.
Whole blood cultures consisted of heparinized blood, an equal
volume of RPMI 1640 tissue culture medium (Highveld Biological,
Lyndhurst, South Africa), and mycobacteria from the specified
volume of mycobacterial stock. After 72 hrs, cells were sediment-
ed, the liquid phase removed, and blood cells disrupted by
hypotonic lysis. Bacilli were recovered and inoculated into MGIT
and incubated until flagged as positive. Log change in viability was
calculated as log(final) – log(initial), where final and initial are the
volumes corresponding to TTP of the completed cultures and its
inoculum control, respectively, based on the titration curve.
Results were expressed as log change per day of whole blood
culture. Cumulative WBA over 24 hrs was calculated as the
AUC0-24, and expressed as Dlog/dNd, or simply as log change.
Minimal inhibitory concentration (MIC) testing
MICs of sutezolid and its major metabolite were determined
using MGIT. Sterile stock solutions of sutezolid and PNU-101603
10 mg/ml were prepared in DMSO. Testing was performed using
a series of 2-fold reductions in drug concentrations from 4.0 to
0.062 mg/ml. Growth in drug-containing tubes was compared to
that of a positive growth control in which the inoculum was diluted
1:100 in saline. The MIC was defined as the lowest concentration
of drug without growth (GU,100) at the time when growth was
detected in the positive control.
Safety reporting
Specific guidance was provided to investigators for the
identification of serious adverse events (SAEs), which were defined
as those resulting in death, being life-threatening, requiring or
prolonging hospitalization, resulting in persistent or significant
disability or incapacity, or resulting in congenital anomaly.
Guidance was provided for classification of abnormal test results
as adverse events and as well as criteria for laboratory
abnormalities of potential clinical concern. Potential cases of
drug-induced liver injury were defined by Hy’s criteria [8]. AE
severity was clinically assessed as mild, moderate, or severe
according to the extent to which it interfered with the subject’s
usual function (none, partially, or significantly). The accuracy of all
entered study data was verified by independent study monitors.
Statistics
The sample size for the sutezolid arms was selected to have 80%
power to detect a change from baseline in sputum log10 CFU/mL
from baseline to day 2 of 20.18 (equal to that observed for
linezolid 600 mg QD), using a one-sided test at the 0.05
significance level, and assuming between subject variability (SD)
of 0.35 [9,10]. Sputum log10 CFU/ml was analyzed by mixed
effects model repeated measures analysis (MMRM), using fixed
effects for treatment, baseline values, study day as a categorical
variable, and study day by treatment interaction, and a random
effect for subject with unstructured within subject covariances
(unstructured to allow for its full estimation from present data).
Rates of change from baseline to day 2, from day 2 to 14, and
from baseline to day 14 were examined. Additional analyses of
sputum log10 CFU/ml were conducted using ANCOVA of
change from beginning to end of each period, using ANCOVA
of changes based on regression slope, and using mixed effects
model repeated measures analysis with day as a regression
variable. 90% confidence limits (5%–95%) were calculated to be
consistent with a one-sided test at the 0.05 significance level.
Changes in MGIT TTP were analyzed similarly. Cumulative
WBA was analyzed by an ANCOVA with fixed effects for
treatment and baseline, and a random effect for subject. MIC
results were analyzed post-treatment vs. pre-treatment post hoc,
separately for parent/metabolite and BID/QD schedules due to
different characteristics and data distributions, by generalized
linear mixed model repeated measures analysis (GLMMRM),
using multinomial cumulative logit link with proportional odds.
GLMMRM is potentially a more sensitive test in the case of
missing data. A nonparametric sign test was also performed post
hoc on MIC results as a sensitivity analysis, as a more conservative
method. Two-sided testing was used on these post hoc analyses.
There was no multiplicity adjustment for tests in different datasets.
Ethical review
This study received ethical approval from the University of
Cape Town Faculty of Health Sciences Human Research Ethics
Committee, Cape Town, South Africa, and from Pharma-Ethics,
Lyttelton Manor, South Africa. The study received regulatory
approval in South Africa and was registered on clinicaltrials.gov as
NCT01225640.
Role of the funding source
This study was funded by Pfizer, Inc. Pfizer employees
contributed to study design, data analysis, and data interpretation.
All authors had full access to all study data and had final
responsibility for the decision to submit for publication. Rights to
sutezolid were acquired by Sequella, Inc. in 2013.
Results
Subjects
Enrollment began at both sites in August 2011; study
participation was completed by December 2011. A CONSORT
flow diagram showing enrollment is shown in figure 1. Subject
demographic and baseline characteristics were similar among the
3 arms (table 1). Subjects were primarily male (80%) and ,45
years of age (81%). Four subjects were HIV-1 seropositive, with
CD4 T cell counts ranging from 643 to 812 cells/ml. The baseline
sputum bacillary burden was approximately 107 CFU/ml, similar
to other EBA trials. All subjects completed their assigned
treatments, began subsequent standard TB treatment without
interruption, and were included in the full analysis set.
Sputum bactericidal activity
Both dosing schedules of sutezolid resulted in changes in sputum
log10 CFU over the entire period of treatment that excluded zero
(table 2 and figure 2 left panel). Separate analysis of days 0–2 and
2–14 showed the effect only was significant during the later
interval. A trend toward a superior effect was apparent in mean
values across days when sutezolid was given as 600 mg BID
(figure 2), but the confidence intervals for the two dosing schedules
largely overlapped (figure 2 and table 2). Effects in HRZE-treated
subjects were similar to those reported in other EBA trials [11].
Changes in MGIT TTP analyzed by MMRM are illustrated in
the right panel of figure 2. Like CFU counts, the 90% CI of the
effects on TTP of both dosing schedules excluded zero. However,
unlike CFU counts, no lag period during early treatment was
apparent (i.e., changes from baseline to day 2 were statistically
significant), nor was any trend apparent toward superiority of
600 mg BID dosing.
Sutezolid EBA and WBA
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Whole blood bactericidal activity
Prior to the start of treatment, there was mean growth of M.
tuberculosis H37Rv of approximately +0.2 log/d in ex vivo whole
blood cultures (table 1), corresponding to a doubling time of
approximately 36 hrs. Sutezolid treatment resulted in readily
detectable bactericidal activity whether administered as a single or
divided dose (figure 3). Both doses produced maximal killing of
approximately 20.4 log/d, occurring 2–3 hrs post dose. Analysis
of cumulative activity over 24 hr by ANCOVA indicated log10
estimates of -0.14260.020 and 2.08960.020 (mean 6 SE) for
BID and QD dosing, respectively. Although the 90% CI of
difference between the 2 schedules excluded zero (20.100 to 2
0.005), the difference only approached significance at the two-
tailed 5% level (P = 0.068). There was no correlation between
cumulative WBA and EBA from baseline to day 2 or from days 2–
14 among sutezolid-treated patients (all R,0.2, P.0.2).
Minimum inhibitory concentrations
MIC testing of sutezolid and its major metabolite was
incomplete, lacking 38/200 (19%) results due to time and resource
constraints. Median MIC values for the parent and metabolite at
baseline were #0.062 mg/ml and 0.500 mg/ml, respectively, in
Figure 1. CONSORT flow diagram of study enrollment.
doi:10.1371/journal.pone.0094462.g001
Table 1. Baseline subject characteristics by treatment arm.
Sutezolid Sutezolid RHZE
600 mg BID 1200 mg QD
Number of subjects 25 25 9
Age (years, mean 6 SD) 32.369.0 34.1611.7 33.8611.8
Sex (male/female) 20/5 20/5 7/2
Race (Black/Other) 11/14 8/17 3/6
Weight (kg, mean 6 SD) 54.666.5 51.166.7 51.367.5
Height (cm, mean 6 SD) 167.468.2 167.066.1 166.5611.8
BMI (kg/m2, mean 6 SD) 19.662.9 18.361.8 18.460.5
Baseline microbiology:
log CFU/ml (mean 6 SD) 6.8861.11* 6.9261.20 7.2260.71
TTP (hours, mean 6 SD) 125.0642.5 106.8634.8 115.4634.1
WBA (Dlog/d, mean 6 SD) 0.1766.126{ 0.2216.080 0.1906.0261
*N= 23; {N= 21; 1N=5. BMI = body mass index; TTP = time to positivity in automated liquid culture; WBA=whole blood bactericidal activity.
doi:10.1371/journal.pone.0094462.t001
Sutezolid EBA and WBA
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both treatment arms. Testing was repeated on day 15 to determine
if values increased due to treatment. In patients treated with
sutezolid 1200 mg QD, the median MIC of the parent on day 15
was 0.125 mg/ml. This reflected 5 instances in which MICs
increased vs. none in which they decreased (figure 4). However, the
significance level of this change (two-tailed GLMMRM: P= .034;
two-tailed sign test: P= .063) does not account for the 4
comparisons conducted for the 4 different datasets (2 treatment
arms, parent and metabolite) in post-hoc testing. All other median
MICs were unchanged (P$.727).
Plasma pharmacokinetics
Plasma concentrations of sutezolid and its major metabolite
(PNU-101603) on day 14 are shown in figure 5. Key PK
parameters are summarized in table 3. While the AUC0 224 values
were comparable between the QD and BID dosing regimens for
both sutezolid and PNU-101603, administration of sutezolid as a
single daily dose resulted in a doubling of the Cmax but slightly
less than a doubling of that of the major metabolite. When dosed
at 600 mg BID, median plasma concentrations of parent and
major metabolite remained above their respective median MIC
values for 71% and 89% of the dosing interval. In contrast, dosing
at 1200 mg QD resulted in median supra-MIC plasma concen-
trations for 53% and 57% of the dosing interval, respectively. The
observed mean AUC0–24 of parent and metabolite appeared to
range from 63–71% and 86–91%, respectively, of values observed
in phase 1, whereas Cmax values of parent and metabolite equaled
those observed in healthy volunteers in phase 1 [5].
Safety
Treatment with sutezolid was generally safe and well tolerated.
No subject required dose reduction or premature discontinuation
Figure 2. Bactericidal activity in sputum according to treatment arm as assessed by colony counts (left) and time to positivity in
automated liquid culture (MGIT TTP, right). Lines indicate prediction and shading 90% confidence interval (CI) as determined by mixed effects
model repeated measures analysis, using day as a categorical variable. The vertical axis of the right hand figure is inverted to facilitate visual
comparison with CFU findings. At 14 days, the 90% CI of all treatments excluded zero.
doi:10.1371/journal.pone.0094462.g002
Table 2. Rate of change of sputum log10 CFU counts per day according to mixed effects modeling repeated measures analysis,
using fixed effects for treatment, day, treatment by day interaction, and baseline values (defined as the mean of days 21 and 0).
Treatment Estimate SE 90% CI P*
Baseline to day 2
Sutezolid 600 mg BID 20.080 0.091 20.232 to 0.072 0.192
Sutezolid 1200 mg QD 20.051 0.088 20.199 to 0.096 0.281
RHZE 20.537 0.148 20.785 to 20.289 0.0003
Day 2 to 14
Sutezolid 600 mg BID 20.090 0.018 20.120 to 20.059 ,.0001
Sutezolid 1200 mg QD 20.070 0.017 20.099 to 20.041 ,.0001
RHZE 20.140 0.030 20.190 to 20.090 ,.0001
Baseline to day 14
Sutezolid 600 mg BID 20.088 0.014 20.112 to 20.065 ,.0001
Sutezolid 1200 mg QD 20.068 0.013 20.090 to 20.045 ,.0001
RHZE 20.197 0.023 20.235 to 20.158 ,.0001
*P values indicate the likelihood of no difference from zero as determined by a one-tailed test.
doi:10.1371/journal.pone.0094462.t002
Sutezolid EBA and WBA
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due to adverse events or abnormal laboratory parameters. There
were no instances of anemia or thrombocytopenia. There was no
effect of sutezolid on the QTc interval, with changes from baseline
to day 14 of 24.2614.5 msec and 23.1612.1 msec (mean6SD)
in the 600 mg BID and 1200 mg QD arms, respectively.
Treatment-emergent adverse events were distributed evenly across
the sutezolid arms and were mainly classified as mild (n = 26) or
moderate (n = 13) in severity. A total of 7 sutezolid-treated subjects
(14%) experienced mild or moderate increases in alanine
transaminase (ALT). Cases were distributed in both men and
women (5:2) and in both the BID and QD treatment arms (4:3).
None occurred in HIV-1 seropositive individuals. No other
predisposing factors were identified. ALT values for these subjects
increased from 34624 IU/L at baseline (mean6SD) to
173634 IU/L on day 15 (reference range, 6–48 IU/L) (figure 6).
ALT increases were accompanied by smaller increases in AST, but
not by changes in alkaline phosphatase or bilirubin. None of the
subjects experienced symptoms of drug-induced liver injury. None
met Hy’s criteria for serious liver injury [8]. All 7 subjects
completed their assigned sutezolid treatment and began standard
TB therapy without interruption. Five of the 7 subjects were
recalled for repeat testing on day 22, by which time values had
declined to 75628 IU/L. Values for all patients had returned to
normal on day 42 (2469 IU/L).
One adverse event met study criteria for both serious and
severe: hemoptysis occurred in 1 subject 14 days after the last dose
of sutezolid 600 mg BID. It was thought by both the investigator
and sponsor to be related to tuberculosis rather than its treatment.
Lastly, one instance of grade 1 peripheral neuropathy occurred in
a patient assigned to sutezolid 600 mg BID. However, its onset
occurred after sutezolid treatment had been completed, and was
attributed by the investigator to the standard TB treatment that
followed. A listing of all treatment-emergent adverse events of all
potential causes can be found in table S1.
Figure 3. Bactericidal activity against M. tuberculosis H37Rv in whole blood culture (WBA) according to treatment arm, at discrete
time points (left), and as cumulative effect (right). Lines and shading indicate means and 90% confidence intervals (CI).
doi:10.1371/journal.pone.0094462.g003
Figure 4. Distributions of minimal inhibitory concentrations (MICs) to sutezolid (PNU-100480) pre and post treatment (rows and
columns, respectively), according to dosing schedule. Values in each cell indicate numbers of patients. Cells shaded red are those in which
MIC values increased, whereas they decreased in those shaded blue. No change was apparent in MIC values of the metabolite (PNU-101603, not
shown).
doi:10.1371/journal.pone.0094462.g004
Sutezolid EBA and WBA
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Discussion
This is the first study of sutezolid in patients with pulmonary
tuberculosis. The main findings were that doses of 600 mg BID
and 1200 mg QD given for 14 days were generally safe, well
tolerated, and resulted in readily detectable bactericidal activity in
both sputum and blood. Its effects in sputum were sustained
throughout the full period of treatment. These findings support
further development of sutezolid as a component of new
tuberculosis regimens.
Prior studies have separately examined the mycobactericidal
activity of linezolid in sputum and blood. One study in a total of
19 TB patients found linezolid 600 mg BID and 600 mg QD
produced effects approaching statistical significance of 20.26 and
20.18 log10 CFU/ml/day, respectively, during the first 2 days of
treatment, but not subsequently [9]. In contrast, the present study
found no significant effect on sputum CFU counts during the first
2 days of treatment, but did find a significant, sustained effect
subsequently. Effects during early TB treatment are thought to
represent activity against extracellular, metabolically active bacilli
in cavities. This bacillary subpopulation is critical for TB
transmission and for the emergence of resistance, but it appears
not to be involved in persistence and relapse. The sustained
activity of sutezolid observed in the present trial may indicate
enhanced ability to sterilize tissues and thereby shorten the
required duration of treatment, as has been shown in the mouse
model [4]. However, there is no evidence at present to indicate a
relationship between EBA during the first 2 weeks of TB treatment
and the total duration required for relapse-free cure [12].
This trial is the first in which intracellular bactericidal activity in
blood of TB patients has been assessed in parallel with that in
sputum. Sutezolid and its main metabolite appear to act against
distinct mycobacterial subpopulations. In vitro, extracellular killing
is mainly due to the metabolite, whereas killing of intracellular
mycobacteria, such as in the whole blood model, is mainly due to
the parent [13,14]. Sutezolid shows superior activity vs. linezolid in
the whole blood model [5]. In one study, whole blood bactericidal
activity during TB treatment correlated with 2 month sputum
culture status [15], which in turn is a predictor of relapse [16].
Longer trials will be required to better assess the sterilizing activity
of sutezolid and to determine the required duration of new
sutezolid-containing regimens. Future trials may also consider
studying each patient using his or her own isolate in whole blood
culture to enhance its predictive value [15].
The mycobactericidal activity of sutezolid in the whole blood
and hollow fiber models is mainly dependent on time rather than
concentration [5,13]. Given this observation, the relatively short
plasma half-lives of both the parent and metabolite (approximately
4 hrs) ordinarily would favor divided rather than single daily
dosing. In the present study, divided dosing tended to show
Figure 5. Plasma concentrations of sutezolid (pink) and its major metabolite (yellow) at steady state (day 13–14) in patients treated
with sutezolid 600 mg BID (left) or 1200 mg QD (right). Solid lines indicate medians; shading indicates 90% CI. Lower and upper dotted lines
indicate median pre-treatment MIC values for parent and metabolite, respectively.
doi:10.1371/journal.pone.0094462.g005
Table 3. Geometric mean pharmacokinetic parameters in patients of sutezolid and its major metabolite following dosing for 14
Days.
Dose N sutezolid (PNU-100480) major metabolite (PNU-101603)
Cmax AUC0-24 Cmax AUC0–24
ng/mL (CV) ngNh/mL (CV) ng/mL (CV) ngNh/mL (CV)
600 mg BID 25 986 (36%) 6494 (35%) 4355 (20%) 39140 (18%)
1200 mg QD 25 1972 (50%) 7127 (36%) 7050 (18%) 36820 (22%)
CV= coefficient of variation.
doi:10.1371/journal.pone.0094462.t003
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superior bactericidal activity in blood, although this at best was
only at the threshold of statistical significance. This trial was
neither intended nor powered to detect a difference between single
and divided daily dosing. Longer clinical trials will be required to
determine the potential clinical impact of single vs. divided daily
dosing when sutezolid is combined with other TB drugs in novel
regimens.
Prevention of resistance is an essential characteristic of TB
drugs. Experience with linezolid indicates this characteristic may
be distinct from EBA, as linezolid lacks sustained EBA [9], yet
shows remarkable ability to prevent acquired resistance even when
added as a single new drug to a failing regimen [3]. No conclusion
can be drawn regarding the MIC findings in this trial due to the
post-hoc nature of the analysis and the relatively small magnitude
of observed increases. However, EBA trials are intended to closely
study a small number of subjects during a short period of
treatment so as to inform the design of future trials. Studies of
sutezolid in the hollow fiber model have reported similarly reduced
bactericidal activity and earlier emergence of resistance with
simulated once daily dosing [6]. Pre- and post-treatment MIC
testing should be considered to assess resistance prevention in
future EBA trials.
Peak concentrations of sutezolid and its main metabolite in TB
patients in this study equaled those observed in previous studies in
healthy volunteers, whereas total exposure to the parent was
reduced by one-quarter. This decreased exposure appears to be
the cause of the reduced bactericidal activity in whole blood
cultures at later time points in patients as compared to those
previously reported in healthy volunteers [5]. Macrophage
production of oxygen radicals is increased in TB as part of the
antimycobacterial host response. Non-enzymatic oxidation may
contribute to sutezolid metabolism. Further studies are warranted
to determine whether the rate of metabolic clearance of sutezolid
slows as inflammation resolves during TB treatment, as this may
restore intracellular bactericidal activity to levels observed in
volunteers.
Mild to moderate increases in hepatic alanine aminotransferase
were observed in 14% of sutezolid-treated subjects in this study. In
contrast, ALT levels had remained within the normal range in all
subjects during phase 1 studies of sutezolid in healthy volunteers.
Early, mild, transient, asymptomatic increases in liver enzymes are
common in patients treated with anti-TB drugs [17]. There is
increasing evidence that these represent heightened susceptibility
to oxidative liver injury due to depletion of glutathione, which
ordinarily protects against such damage. Intracellular stores of
glutathione are depleted, and the ratio of reduced to oxidized
glutathione diminished, following experimental M. tuberculosis
infection of guinea pigs [18]. Glutathione levels are low in TB
patients, with the lowest levels occurring in those patients who go
on to experience TB drug-induced liver injury [19–21]. Cysteine
availability is the limiting step in glutathione synthesis. A small
prospective randomized trial reported that TB drug-induced liver
injury could be prevented by supplementation with N-acetylcys-
teine (NAC) [22]. A study of NAC may be considered to reduce
overall risk in future trials of new TB drugs, including sutezolid.
In summary, this first trial of the oxazolidinone sutezolid in
patients with pulmonary tuberculosis found the drug to be
generally safe, well tolerated, and with readily detectable
bactericidal activity in sputum and blood. Further studies of this
promising compound are warranted.
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